Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average) (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $161.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.73% to $161.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $161.8 million through Dec 2025, up 1.73% year-over-year, with the annual reading at $161.8 million for FY2025, 1.73% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $161.8 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $161.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $162.2 million in Q4 2021 to a low of $154.4 million in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $158.6 million across 5 years, with a median of $159.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): decreased 4.86% in 2022 and later grew 2.88% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $162.2 million in 2021, then fell by 4.86% to $154.4 million in 2022, then rose by 0.69% to $155.4 million in 2023, then grew by 2.35% to $159.1 million in 2024, then increased by 1.73% to $161.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IRWD at $161.8 million in Q4 2025, $161.6 million in Q3 2025, and $161.4 million in Q2 2025.